FR16C0043I1 - - Google Patents
Info
- Publication number
- FR16C0043I1 FR16C0043I1 FR16C0043C FR16C0043I1 FR 16C0043 I1 FR16C0043 I1 FR 16C0043I1 FR 16C0043 C FR16C0043 C FR 16C0043C FR 16C0043 I1 FR16C0043 I1 FR 16C0043I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22935800P | 2000-04-12 | 2000-04-12 | |
US19938400P | 2000-04-25 | 2000-04-25 | |
US25693100P | 2000-12-21 | 2000-12-21 | |
EP06076852A EP1832599A3 (en) | 2000-04-12 | 2001-04-12 | Albumin fusion proteins |
EP01934875A EP1278767A4 (en) | 2000-04-12 | 2001-04-12 | ALBUMIN FUSED PROTEINS |
EP08075909A EP2067488A1 (en) | 2000-04-12 | 2001-04-12 | Albumin fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0043I1 true FR16C0043I1 (es) | 2016-12-09 |
FR16C0043I2 FR16C0043I2 (fr) | 2020-04-10 |
Family
ID=27394014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0043C Active FR16C0043I2 (fr) | 2000-04-12 | 2016-11-04 | Proteines de fusion d'albumine |
Country Status (10)
Country | Link |
---|---|
US (23) | US6926898B2 (es) |
EP (21) | EP2267026A1 (es) |
JP (9) | JP2003531590A (es) |
AU (7) | AU2001259066A1 (es) |
BE (1) | BE2016C059I2 (es) |
CA (8) | CA2405525A1 (es) |
DK (2) | DK2216409T3 (es) |
ES (2) | ES2529300T3 (es) |
FR (1) | FR16C0043I2 (es) |
WO (7) | WO2001079442A2 (es) |
Families Citing this family (645)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
WO2002024719A1 (en) * | 2000-09-20 | 2002-03-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US20030170794A1 (en) * | 1997-09-18 | 2003-09-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
EP1088084B1 (en) * | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
DE69926009D1 (de) | 1998-10-13 | 2005-08-04 | Univ Georgia Res Found | Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung |
DK2230303T3 (da) * | 1999-05-05 | 2013-04-15 | Phylogica Ltd | Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US20020049312A1 (en) * | 2000-05-23 | 2002-04-25 | Turner C. Alexander | Noel human thrombospondin-like proteins and polynucleotides encoding the same |
EP1224285A4 (en) * | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
JP2003520030A (ja) * | 1999-11-05 | 2003-07-02 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 28個のヒト分泌タンパク質 |
EP1235845A4 (en) * | 1999-11-05 | 2003-06-25 | Human Genome Sciences Inc | 24 HUMAN SECRETED PROTEINS |
JP2003520031A (ja) * | 1999-11-12 | 2003-07-02 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 28個のヒト分泌タンパク質 |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
AU784285B2 (en) | 1999-12-24 | 2006-03-02 | Genentech Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7534417B2 (en) | 2000-02-24 | 2009-05-19 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2267026A1 (en) | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
WO2001085936A1 (en) * | 2000-05-12 | 2001-11-15 | Merck Patent Gmbh | F-box containing protein |
US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
WO2001094391A2 (en) * | 2000-06-08 | 2001-12-13 | Incyte Genomics, Inc. | Intracellular signaling proteins |
US7329729B1 (en) * | 2000-06-21 | 2008-02-12 | Amgen Inc. | Secreted epithelial colon stromal-1 molecules and uses thereof |
CA2419306A1 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | 23 human secreted proteins |
CA2418676A1 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
AU2001229509A1 (en) * | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | 11 human secreted proteins |
CA2420902A1 (en) * | 2000-08-28 | 2002-03-07 | Craig A. Rosen | 18 human secreted proteins |
EP1330466A4 (en) * | 2000-09-29 | 2004-03-24 | Human Genome Sciences Inc | 24 HUMANE SECONDED PROTEINS |
AU2001296235A1 (en) * | 2000-10-12 | 2002-04-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6949371B2 (en) | 2000-10-20 | 2005-09-27 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
FR2815964A1 (fr) * | 2000-10-30 | 2002-05-03 | Inst Nat Sante Rech Med | Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications |
EP1395657B1 (en) * | 2000-12-05 | 2007-04-18 | Wisconsin Alumni Research Foundation | Receptor for bacillus anthracis toxin |
ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
US20030148920A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
JP4344519B2 (ja) * | 2000-12-28 | 2009-10-14 | 旭化成ファーマ株式会社 | NF−κB活性化遺伝子 |
CA2433469A1 (en) * | 2001-02-23 | 2002-09-06 | Human Genome Sciences, Inc. | 83 human secreted proteins |
WO2002072138A1 (en) * | 2001-03-08 | 2002-09-19 | Hyseq, Inc. | Methods and materials relating to fibulin-like polypeptides and polynucleotides |
CA2443123A1 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030125521A1 (en) | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP1405077A2 (en) * | 2001-07-06 | 2004-04-07 | Geneprot, Inc. | Carcinoma-related peptides |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
KR100406760B1 (ko) * | 2001-11-16 | 2003-11-21 | 신코엠 주식회사 | 반도체 메모리 장치 |
US7553483B2 (en) | 2001-12-17 | 2009-06-30 | Merck Serono Sa | Chemokine mutants acting as chemokine antagonists |
US20040082761A1 (en) * | 2001-12-18 | 2004-04-29 | Duggan Brendan M. | Cell adhesion proteins |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
US20050222023A1 (en) * | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
WO2003066078A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Hiv inhibiting proteins |
DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
US7572763B2 (en) * | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
CA2477614A1 (en) * | 2002-03-05 | 2003-09-18 | Merck & Co., Inc. | Biomarker for efficacy of appetite suppressant drugs |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
WO2003088990A1 (en) * | 2002-04-15 | 2003-10-30 | American National Red Cross | Plasma protein-binding ligands |
US20070015230A1 (en) * | 2002-04-15 | 2007-01-18 | Hammond David J | Identification and characterization of analytes from whole blood |
EP1490108A4 (en) | 2002-04-18 | 2006-08-09 | Gen Hospital Corp | DRAG11 GENERAL FAMILY (DRAGON) |
US7141381B2 (en) | 2002-04-25 | 2006-11-28 | Bristol-Myers Squibb Company | Human leucine-rich repeat-containing proteins specifically expressed in the nervous system |
GB0210464D0 (en) | 2002-05-08 | 2002-06-12 | Svanborg Catharina | Therapeutic treatment |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
EP1531850B1 (en) * | 2002-06-07 | 2012-02-22 | ZymoGenetics, Inc. | Use of IL-21 and monoclonal antibody for treating solid cancers |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
CN101172091B (zh) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
AU2003245089A1 (en) * | 2002-07-03 | 2004-01-23 | Nexgen Biotechnologies, Inc. | Fusion polypeptide comprising epidermal growth factor and human serum albumin |
EP2332956A1 (en) * | 2002-07-08 | 2011-06-15 | Genentech, Inc. | Antibody binding to PRO71238 |
CA2493263A1 (en) * | 2002-07-22 | 2004-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel gene associated with rheumatoid arthritis |
GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
WO2004015113A2 (en) * | 2002-08-07 | 2004-02-19 | Delta Biotechnology Ltd. | Albumin-fused ciliary neurotrophic factor |
CA2495459C (en) * | 2002-08-13 | 2009-10-27 | Arbios Technologies Inc. | Selective plasma exchange therapy |
SI2386310T1 (sl) | 2002-08-28 | 2019-03-29 | Dyax Corp. | Metode za ohranjanje organov in tkiv |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20040115194A1 (en) * | 2002-09-06 | 2004-06-17 | Yi Wang | Method of treatment of asthma using antibodies to complement component C5 |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
CN1688696A (zh) * | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1572739B1 (en) * | 2002-12-20 | 2008-07-16 | Geneos OY | Asthma susceptibility locus |
US20060110393A1 (en) * | 2002-12-26 | 2006-05-25 | Eiji Sunahara | Novel proteins and use thereof |
EP2325301B1 (en) * | 2003-02-11 | 2015-09-02 | Shire Human Genetic Therapies, Inc. | Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE) |
US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
AU2004220525B2 (en) * | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
WO2004082640A2 (en) * | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
US20060233808A1 (en) * | 2003-04-04 | 2006-10-19 | David Deperthes | Peptabody for cancer treatment |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
WO2004094589A2 (en) * | 2003-04-18 | 2004-11-04 | Incyte Corporation | Secreted proteins |
WO2004101620A2 (en) * | 2003-05-01 | 2004-11-25 | Compound Therapeutics, Inc. | Serum albumin scaffold-based proteins and uses thereof |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
EP1650302B1 (en) * | 2003-06-30 | 2012-03-21 | Nihon University | Protein capable of deposition onto extracellular matrix |
EP1644408A1 (en) | 2003-07-15 | 2006-04-12 | Barros Research Institute | Eimeria tenella antigen for immunotherapy of coccidiosis |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
GB0320877D0 (en) * | 2003-09-05 | 2003-10-08 | Celltech R&D Ltd | A protein involved in carcinoma |
DK1682178T3 (da) | 2003-11-04 | 2010-10-04 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet |
EP1704164B1 (en) * | 2003-12-03 | 2011-12-28 | Kröz, Monika | Interleukin-11 fusion proteins |
CN100379762C (zh) * | 2003-12-08 | 2008-04-09 | 中国人民解放军军事医学科学院生物工程研究所 | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
WO2005058961A2 (en) | 2003-12-12 | 2005-06-30 | Amgen Inc. | Antibodies specific for human galanin, and uses thereof |
GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
JPWO2005061704A1 (ja) * | 2003-12-24 | 2007-07-12 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
SE0400489D0 (sv) * | 2004-02-27 | 2004-02-27 | Biovitrum Ab | Therapeutic proteins |
DE602005019540D1 (de) * | 2004-03-03 | 2010-04-08 | Evotec Neurosciences Gmbh | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten |
US20050201959A1 (en) * | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
EP1740047A2 (en) * | 2004-03-11 | 2007-01-10 | Kythera Biopharmaceuticals, Inc. | Compositions and methods for preventing and treating skin and hair conditions |
CN102718867A (zh) | 2004-03-12 | 2012-10-10 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
WO2005115444A2 (en) * | 2004-04-14 | 2005-12-08 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
CN1956998B (zh) * | 2004-04-23 | 2012-12-12 | 康久有限责任公司 | 用于纯化白蛋白结合物的方法 |
KR100599454B1 (ko) * | 2004-04-27 | 2006-07-12 | 재단법인서울대학교산학협력재단 | 종양 억제자로 작용하는 aim3의 신규 용도 |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US8008020B2 (en) * | 2004-06-03 | 2011-08-30 | Vermillion, Inc. | Biomarkers for peripheral artery disease |
WO2006009825A1 (en) | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
WO2006019904A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Netrin-related compositions and uses |
CA2576624A1 (en) * | 2004-08-13 | 2006-03-16 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2301963A1 (en) | 2004-09-23 | 2011-03-30 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20060078541A1 (en) * | 2004-10-01 | 2006-04-13 | Giles Brian C | Method and formula for stem cells' stimulation, targeting release, trafficking and homing |
EP3428191A1 (en) | 2004-10-06 | 2019-01-16 | Mayo Foundation for Medical Education and Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
WO2006042197A2 (en) * | 2004-10-11 | 2006-04-20 | The Board Of Trustees Of The Leland Standford Junior University | Use of del-1 in hair, bone and cartilage regeneration |
CA2585364C (en) * | 2004-10-25 | 2014-05-13 | Immune System Key Ltd | A thymus-specific protein |
KR100583350B1 (ko) * | 2004-11-03 | 2006-06-05 | (주)넥스젠 | Fas-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법 |
CN101087805B (zh) * | 2004-11-09 | 2012-05-23 | 阿雷斯贸易股份有限公司 | Fsh的纯化方法 |
DK2330200T3 (en) | 2004-12-23 | 2017-07-24 | Albumedix As | GENE EXPRESSION TECHNIQUE |
EP1835929B8 (en) | 2005-01-06 | 2016-07-27 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US20060178301A1 (en) * | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
CN105535967B (zh) | 2005-02-15 | 2022-05-03 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
JP2008537488A (ja) * | 2005-03-23 | 2008-09-18 | ワイス | Gdf−8モジュレート物質の検出 |
MX2007011405A (es) * | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de una respuesta inmune para agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
US8034326B2 (en) | 2005-04-18 | 2011-10-11 | Novo Nordisk A/S | IL-21 variants |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
EP1874821B1 (de) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
US8653028B2 (en) | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
JP2008546426A (ja) * | 2005-05-12 | 2008-12-25 | ザイモジェネティクス, インコーポレイテッド | T細胞を共刺激するためにpHHLA2を使用する方法 |
MX349137B (es) | 2005-06-08 | 2017-07-13 | Dana-Farber Cancer Inst | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
WO2007014167A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions for and methods of treating epithelial diseases with growth factors |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8217147B2 (en) | 2005-08-10 | 2012-07-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US20080219952A1 (en) | 2005-08-26 | 2008-09-11 | Ares Trading S.A. | Process For the Preparation of Glycosylated Interferon Beta |
US7713715B2 (en) * | 2005-09-06 | 2010-05-11 | University Of Tennessee Research Foundation | Method for diagnosing infections |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
EP1929073A4 (en) * | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
CN101321863A (zh) * | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 具有受调控的血浆半衰期的融合蛋白 |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1960419B1 (en) * | 2005-12-09 | 2016-03-16 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
BRPI0619586A2 (pt) * | 2005-12-09 | 2018-08-28 | Seattle Genetics Inc | método para o tratamento ou prevenção de um distúrbio associado com cd40 |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
CN101384623B (zh) * | 2005-12-22 | 2013-07-24 | 常山凯捷健生物药物研发(河北)有限公司 | 白蛋白与治疗剂的预成型偶联物的制备方法 |
US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
WO2007082154A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
EP1989326A4 (en) | 2006-01-17 | 2009-09-30 | Health Research Inc | HETERO DUPLEX TRACKING TEST |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
SG170837A1 (en) * | 2006-04-05 | 2011-05-30 | Abbott Biotech Ltd | Antibody purification |
DK2007885T3 (da) * | 2006-04-11 | 2010-11-08 | Csl Behring Gmbh | Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
BRPI0712383A2 (pt) | 2006-06-07 | 2012-07-10 | Human Genome Sciences Inc | proteìnas de fusão da albumina |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
JP5800458B2 (ja) * | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
WO2008007146A1 (en) * | 2006-07-13 | 2008-01-17 | Upperton Limited | Process for preparing particles of proteinaceous material |
ATE524493T1 (de) | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
WO2008019036A2 (en) * | 2006-08-04 | 2008-02-14 | Pharmathene Inc. | Long half-life recombinant butyrylcholinesterase |
AU2007292295B2 (en) * | 2006-09-06 | 2013-06-06 | Immunoforge Co., Ltd. | Fusion peptide therapeutic compositions |
DK2615108T3 (en) | 2006-09-08 | 2017-01-30 | Ambrx Inc | Modified human plasma polypeptide or fc scaffolds and their applications |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
CA2667678A1 (en) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2666426A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
AU2007322265B2 (en) | 2006-11-07 | 2013-06-20 | Merck Sharp & Dohme Corp. | Antagonists of PCSK9 |
AU2007331195A1 (en) | 2006-12-12 | 2008-06-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
AU2007336242B2 (en) | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
EP2423221B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
EP2109457B1 (en) * | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
EP2142217B1 (en) | 2007-03-27 | 2014-11-05 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted pcsk9 |
JP5575636B2 (ja) | 2007-05-07 | 2014-08-20 | メディミューン,エルエルシー | 抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用 |
JP2010527356A (ja) | 2007-05-14 | 2010-08-12 | メディミューン,エルエルシー | 好酸球レベルを低下させる方法 |
EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
WO2009012502A1 (en) * | 2007-07-19 | 2009-01-22 | The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Self- anchoring mems intrafascicular neural electrode |
JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
NO2195023T3 (es) | 2007-08-29 | 2018-08-04 | ||
JP2009055838A (ja) * | 2007-08-31 | 2009-03-19 | Nipro Corp | 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物 |
CN108129573B (zh) * | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
AU2008314687A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying Fc-fusion proteins |
AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
EP2604628A3 (en) | 2007-12-21 | 2013-08-21 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
US20100311072A1 (en) * | 2008-01-28 | 2010-12-09 | Bristol-Myers Squibb Company | Fluorescence polarization binding assay for characterizing glucokinase ligands |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
JP5020135B2 (ja) * | 2008-03-19 | 2012-09-05 | ソニーモバイルコミュニケーションズ, エービー | 携帯端末装置およびコンピュータプログラム |
US9242011B2 (en) | 2008-04-01 | 2016-01-26 | Novo Nordisk A/S | Insulin albumin conjugates |
EP2260058A2 (en) | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
PT2274331E (pt) | 2008-05-02 | 2014-02-27 | Novartis Ag | Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações |
PL2291523T3 (pl) * | 2008-06-24 | 2015-05-29 | Csl Behring Gmbh | Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo |
AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
EP2313093A4 (en) | 2008-07-10 | 2012-03-28 | Angion Biomedica Corp | METHOD AND COMPOSITIONS FOR LOW-MOLECULAR MODULATORS OF THE HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY |
EP2313436B1 (en) | 2008-07-22 | 2014-11-26 | Ablynx N.V. | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
EP2815766B1 (en) | 2008-08-05 | 2017-07-05 | Novartis AG | Compositions and methods for antibodies targeting complement protein C5 |
RS54233B1 (en) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION |
US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
AU2008361352B2 (en) | 2008-09-07 | 2013-05-09 | Glyconex Inc. | Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use |
CA2743469C (en) | 2008-11-12 | 2019-01-15 | Medimmune, Llc | Antibody formulation |
JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
BRPI0921321A2 (pt) | 2008-11-28 | 2018-10-16 | Emory University | métodos para o tratamento de indwcções e tumores |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CN102378635A (zh) | 2009-01-16 | 2012-03-14 | 特瓦制药工业有限公司 | 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂 |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2393828B1 (en) | 2009-02-03 | 2016-10-12 | Amunix Operating Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US9493545B2 (en) | 2009-02-11 | 2016-11-15 | Albumedix A/S | Albumin variants and conjugates |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
WO2010128142A1 (en) | 2009-05-07 | 2010-11-11 | Novozymes Biopharma Dk A/S | Method for purifying albumin |
WO2010138555A2 (en) * | 2009-05-26 | 2010-12-02 | University Of Florida Research Foundation, Inc. | Small peptide expression system in mammalian cells |
EP2258398A1 (en) * | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
EP2440228B8 (en) | 2009-06-08 | 2023-02-22 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
CN101628346B (zh) * | 2009-07-25 | 2012-05-16 | 大连理工大学 | 一种减缓碳纤维复合材料手工制孔出口速度的方法及其缓冲装置 |
EP3381937A3 (en) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
CA2770609A1 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
US8451450B2 (en) * | 2009-09-14 | 2013-05-28 | Bio-Rad Laboratories, Inc. | Near real time optical phase conjugation |
US20110195494A1 (en) | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
UY32920A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
RU2583298C2 (ru) | 2009-10-07 | 2016-05-10 | Макродженикс, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
EP2493916B1 (en) * | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
WO2011053783A2 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax213 and ax132 pcsk9 antagonists and variants |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
EP3421491A3 (en) | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Albumin variants |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
CA2817671A1 (en) * | 2009-11-17 | 2011-05-26 | Universite De Montreal | Heteropeptides useful for reducing nonspecific adsorption |
EP4382170A2 (en) | 2009-12-06 | 2024-06-12 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
MX2012006462A (es) | 2009-12-08 | 2012-10-03 | Teva Pharma | Fusiones de albumina bche para el tratamiento de abuso de cocaina. |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011084145A2 (en) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
CN103002918B (zh) | 2010-01-22 | 2016-05-04 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
WO2011100460A2 (en) * | 2010-02-11 | 2011-08-18 | Ecole Polytechnique Federale De Lausanne | Ccr7 ligand delivery and co-delivery in immunotherapy |
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
KR20130066631A (ko) | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | 치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법 |
ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
WO2011144749A1 (en) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Biological materials related to her3 |
MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
EP3508573A1 (en) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合療法 |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
EP2608807A1 (en) | 2010-08-27 | 2013-07-03 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
SG10201506959SA (en) | 2010-09-03 | 2015-10-29 | Stemcentrx Inc | Novel modulators and methods of use |
US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
EA201370076A1 (ru) | 2010-09-22 | 2013-08-30 | Амген Инк. | Иммуноглобулины-переносчики и их применение |
PT2621519T (pt) | 2010-09-28 | 2017-10-04 | Aegerion Pharmaceuticals Inc | Polipéptido de fusão de leptina-abd com duração de ação melhorada |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
US8853490B2 (en) * | 2010-10-26 | 2014-10-07 | Pioneer Hi Bred International Inc | Antifungal proteins and methods of use |
WO2012059486A1 (en) | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
EP3578568A3 (en) | 2010-11-08 | 2020-01-08 | Ablynx N.V. | Cxcr2 binding polypeptides |
US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
AU2011360938B2 (en) | 2010-12-08 | 2016-07-28 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
EP2660600B1 (en) | 2010-12-28 | 2018-08-08 | Sumitomo Dainippon Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
CN103732628B (zh) | 2011-03-03 | 2017-06-23 | 酵活有限公司 | 多价杂多聚体骨架设计和构建体 |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
EP2683397B1 (en) | 2011-03-09 | 2017-08-09 | CSL Behring GmbH | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
US9340590B2 (en) | 2011-03-16 | 2016-05-17 | Amgen Inc. | Potent and selective inhibitors of NaV1.3 and NaV1.7 |
EP3235508B1 (en) | 2011-03-16 | 2020-12-30 | Sanofi | Compositions comprising a dual v region antibody-like protein |
WO2012135500A1 (en) | 2011-03-29 | 2012-10-04 | The General Hospital Corporation | Engineered thioredoxin-like fold proteins |
EP2691156A1 (en) | 2011-03-30 | 2014-02-05 | Boehringer Ingelheim International GmbH | Anticoagulant antidotes |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20130078247A1 (en) | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
CN105601741A (zh) | 2011-04-15 | 2016-05-25 | 卡姆普根有限公司 | 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途 |
EP2515112B1 (en) * | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US8822417B2 (en) * | 2011-05-05 | 2014-09-02 | Novozymes Biopharma DIC A/S | Albumin variants |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
AU2012267484B2 (en) | 2011-06-10 | 2017-03-23 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
EP2726092B1 (en) | 2011-06-28 | 2019-06-19 | Inhibrx, LP | Serpin fusion polypeptides and methods of use thereof |
BR112014000055A2 (pt) | 2011-07-01 | 2017-06-13 | Bayer Ip Gmbh | polipeptídeos de fusão de relaxina e usos dos mesmos |
EP2729492B1 (en) | 2011-07-05 | 2019-01-02 | Albumedix Ltd | Albumin formulation and use |
DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
BR112014000474A2 (pt) | 2011-07-08 | 2017-02-21 | Bayer Ip Gmbh | proteínas de fusão libertadoras de relaxina e suas utilizações |
RU2014103185A (ru) * | 2011-07-18 | 2015-08-27 | Артс Байолоджикс А/С | Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием |
IL230564B2 (en) | 2011-07-22 | 2023-09-01 | Csl Ltd | Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses. |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US8993831B2 (en) * | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
CN104053671A (zh) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | 治疗癌症的抗体和方法 |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
RU2014122602A (ru) | 2011-11-04 | 2015-12-10 | Новартис Аг | Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования |
PT2773671T (pt) | 2011-11-04 | 2021-12-14 | Zymeworks Inc | Geração de anticorpo heterodimérico estável com mutações no domínio fc |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
KR20140103135A (ko) | 2011-12-05 | 2014-08-25 | 노파르티스 아게 | Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
KR102083957B1 (ko) | 2011-12-05 | 2020-03-04 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
CA2858984C (en) | 2011-12-22 | 2021-01-05 | Csl Behring Gmbh | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
LT2804623T (lt) | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
HUE043537T2 (hu) | 2012-02-15 | 2019-08-28 | Bioverativ Therapeutics Inc | Rekombináns VIII faktor fehérjék |
SG11201404943PA (en) | 2012-02-15 | 2014-10-30 | Ecole Polytech | Erythrocyte-binding therapeutics |
EP2814502B1 (en) * | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
UA115781C2 (uk) | 2012-02-27 | 2017-12-26 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cx3cr1-зв'язуючий поліпептид |
BR112014018679A2 (pt) | 2012-03-16 | 2017-07-04 | Novozymes Biopharma Dk As | variantes de albumina |
GB201204868D0 (en) * | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
US9550819B2 (en) | 2012-03-27 | 2017-01-24 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
AU2013258834B2 (en) | 2012-05-10 | 2017-09-07 | Zymeworks Bc Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
EP3318128A3 (en) | 2012-05-30 | 2018-06-27 | Bayer CropScience Aktiengesellschaft | Composition comprising a biological control agent and a fungicide |
EP2854546B1 (en) | 2012-05-30 | 2018-07-04 | Bayer Cropscience AG | Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis |
BR112014029122A8 (pt) | 2012-05-30 | 2019-09-10 | Bayer Cropscience Ag | composições que compreendem um agente de controle biológico e um inseticida |
BR112014029224A2 (pt) | 2012-05-30 | 2017-06-27 | Bayer Cropscience Ag | composição que compreende um agente de controle biológico e um fungicida |
EP2854535A1 (en) | 2012-05-30 | 2015-04-08 | Bayer Cropscience AG | Compositions comprising a biological control agent and an insecticide |
HUE040336T2 (hu) | 2012-05-30 | 2019-03-28 | Bayer Cropscience Ag | Biológiai hatóanyagot és fluopikolidot tartalmazó készítmény |
EP2854551A1 (en) | 2012-05-30 | 2015-04-08 | Bayer Cropscience AG | Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii. |
NZ725224A (en) | 2012-05-30 | 2018-04-27 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
JP6285423B2 (ja) | 2012-05-30 | 2018-02-28 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 生物農薬および殺虫剤を含む組成物 |
WO2013178656A1 (en) | 2012-05-30 | 2013-12-05 | Bayer Cropscience Ag | Composition comprising a biological control agent and a fungicide |
EP3292764A3 (en) | 2012-05-30 | 2018-04-25 | Bayer CropScience Aktiengesellschaft | Composition comprising a biological control agent and a fungicide selected from inhibitors of the respiratory chain at complex iii |
MX360057B (es) | 2012-05-30 | 2018-10-19 | Bayer Cropscience Ag | Composiciones que comprenden un agente de control biologico y un insecticida. |
JP2015521589A (ja) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | プロコアグラント化合物 |
JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | キメラ性凝固因子 |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
LT2882450T (lt) | 2012-07-11 | 2020-03-25 | Bioverativ Therapeutics Inc. | Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas |
JP6498601B2 (ja) | 2012-07-13 | 2019-04-10 | ザイムワークス,インコーポレイテッド | 多価ヘテロ多量体足場設計および構築物 |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
BR112015010318A2 (pt) | 2012-11-08 | 2017-08-22 | Albumedix As | Variantes de albumina |
RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
PT2928921T (pt) | 2012-12-05 | 2021-04-06 | Novartis Ag | Composições e métodos para anticorpos que visam epo |
WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
WO2014113359A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
KR101503907B1 (ko) * | 2013-01-17 | 2015-03-20 | 서울대학교산학협력단 | 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
JP6272907B2 (ja) | 2013-01-30 | 2018-01-31 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害の処置における組成物及び使用方法 |
US20150373973A1 (en) | 2013-02-11 | 2015-12-31 | Bayer Cropscience Lp | Compositions comprising gougerotin and a biological control agent |
RS61387B1 (sr) | 2013-02-15 | 2021-02-26 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
AU2014217831A1 (en) | 2013-02-16 | 2015-07-16 | Albumedix Ltd. | Pharmacokinetic animal model |
ES2609070T3 (es) | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
KR102403299B1 (ko) | 2013-03-08 | 2022-06-03 | 체에스엘 베링 게엠베하 | 원격 허혈-재관류 손상의 치료 및 예방 |
CA2940513C (en) | 2013-03-11 | 2023-08-15 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for ocular inflammation |
WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
EP2968498A4 (en) | 2013-03-15 | 2016-09-07 | Biogen Ma Inc | PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
ES2768648T3 (es) | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
EP2981282B1 (en) * | 2013-04-05 | 2020-11-04 | Novo Nordisk Health Care AG | Growth hormone compound formulation |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
UY35620A (es) | 2013-06-21 | 2015-01-30 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
KR20160026905A (ko) | 2013-06-28 | 2016-03-09 | 체에스엘 베링 게엠베하 | 인자 xii 억제제 및 c1-억제제를 이용한 병용 치료요법 |
EP3013358A4 (en) | 2013-06-28 | 2017-03-22 | Biogen MA Inc. | Thrombin cleavable linker with xten and its uses thereof |
CN104342420B (zh) * | 2013-07-30 | 2017-09-15 | 惠觅宙 | 一种重组长效人透明质酸酶、其编码基因、生产方法及应用 |
WO2015023894A1 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
KR20160044042A (ko) | 2013-08-28 | 2016-04-22 | 스템센트알엑스 인코포레이티드 | 부위-특이적 항체 접합 방법 및 조성물 |
US9993566B2 (en) | 2013-08-28 | 2018-06-12 | Abbvie Stemcentrx Llc | SEZ6 modulators and methods of use |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
CN103468662A (zh) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3470081A1 (en) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015057403A2 (en) * | 2013-10-17 | 2015-04-23 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of inflammatory bowel disease |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
KR101977449B1 (ko) * | 2013-11-01 | 2019-05-10 | 유니버시티에트 이 오슬로 | 알부민 변이체 및 이의 용도 |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
CN116731201A (zh) | 2014-01-10 | 2023-09-12 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
AU2015233084B2 (en) | 2014-02-21 | 2020-12-17 | Anokion Sa | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
ES2911714T3 (es) | 2014-03-11 | 2022-05-20 | Univ Florida | Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria |
US20170107294A1 (en) * | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
WO2015160618A1 (en) | 2014-04-16 | 2015-10-22 | Bayer Cropscience Lp | Compositions comprising ningnanmycin and a biological control agent |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
BR112016025470A2 (pt) | 2014-05-02 | 2017-08-15 | Cerenis Therapeutics Holding S A | ?hdl terapêutico? |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
CN105198999A (zh) * | 2014-05-27 | 2015-12-30 | 上海生物制品研究所有限责任公司 | 一种融合蛋白、其制备方法及其应用 |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
KR102513050B1 (ko) | 2014-06-18 | 2023-03-29 | 체에스엘 베링 게엠베하 | 신경외상성 장애에서의 인자 xii 억제제를 이용한 치료요법 |
WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
AU2015279525A1 (en) | 2014-06-24 | 2016-12-15 | Novo Nordisk A/S | MIC-1 fusion proteins and uses thereof |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
WO2016020880A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
WO2016020882A2 (en) | 2014-08-07 | 2016-02-11 | Novartis Ag | Angiopoetin-like 4 (angptl4) antibodies and methods of use |
JP6886917B2 (ja) | 2014-08-22 | 2021-06-16 | 國立成功大學National Cheng Kung University | ロドストミンバリアント、ロドストミンバリアントをコードするポリヌクレオチド、当該ポリヌクレオチドを含む組換え宿主細胞、及びロドストミンバリアントを含む医薬組成物 |
MX2017003452A (es) | 2014-09-17 | 2017-07-28 | Bayer Cropscience Lp | Composiciones que comprenden celulas recombinantes de bacillus y otro agente de control biologico. |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
AU2015323769A1 (en) | 2014-09-26 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
US9920118B2 (en) | 2014-10-31 | 2018-03-20 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
SG11201705019PA (en) * | 2014-12-23 | 2017-07-28 | Merz Pharma Gmbh & Co Kgaa | Botulinum toxin prefilled container |
AU2016242866B2 (en) * | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
JP2016204292A (ja) * | 2015-04-21 | 2016-12-08 | 国立大学法人 熊本大学 | Bmp7変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤 |
CN107531771A (zh) * | 2015-04-29 | 2018-01-02 | 意大利梅迪奥兰制药公司 | 可溶性嵌合白细胞介素‑10受体和其治疗用途 |
WO2016195723A1 (en) * | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
BR112017021484A2 (pt) | 2015-06-05 | 2018-07-03 | Novartis Ag | anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos |
JP2018524067A (ja) * | 2015-06-11 | 2018-08-30 | アットウィル メディカル ソルーションズ インコーポレイテッド | アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法 |
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
JP2018522030A (ja) * | 2015-07-30 | 2018-08-09 | エンドール テクノロジーズ, エス.エレ.Endor Technologies, S.L. | 膵癌又は大腸癌の治療用コロニー刺激因子 |
CN108350072B (zh) | 2015-08-03 | 2022-05-24 | 诺华股份有限公司 | 治疗fgf21相关病症的方法 |
EP3331608A4 (en) | 2015-08-03 | 2019-05-01 | Bioverativ Therapeutics Inc. | FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME |
AU2016302335B2 (en) * | 2015-08-06 | 2022-08-04 | The Trustees Of The University Of Pennsylvania | GLP-1 and use thereof in compositions for treating metabolic diseases |
CN108137674B (zh) | 2015-08-20 | 2022-12-06 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体和缀合物 |
SI3348635T1 (sl) | 2015-09-08 | 2021-08-31 | Jcr Pharmaceuticals Co., Ltd. | Novi mutant humanega serumskega albumina |
AU2016320748B2 (en) | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
EP3347377B1 (en) | 2015-09-09 | 2021-02-17 | Novartis AG | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
CN108430518A (zh) * | 2015-09-11 | 2018-08-21 | 小利兰·斯坦福大学托管委员会 | 生物相关正交细胞因子/受体对 |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
WO2017093478A1 (en) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
UY37030A (es) | 2015-12-18 | 2017-07-31 | Novartis Ag | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos |
CN108367053A (zh) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
IL260218B2 (en) | 2016-01-11 | 2023-04-01 | Novartis Ag | Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
AU2017214378B2 (en) | 2016-02-01 | 2023-05-04 | Bioverativ Therapeutics Inc. | Optimized Factor VIII genes |
EP3431508A4 (en) | 2016-03-14 | 2019-08-14 | JCR Pharmaceuticals Co., Ltd. | SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN |
JP2019509322A (ja) | 2016-03-22 | 2019-04-04 | バイオノミクス リミテッド | 抗lgr5モノクローナル抗体の投与 |
JP7021099B2 (ja) | 2016-03-31 | 2022-02-18 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 結合タンパク質及びその使用方法 |
CA3019851A1 (en) | 2016-04-06 | 2017-10-12 | Csl Limited | Method of treating atherosclerosis |
US11312766B2 (en) | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
LT3458478T (lt) | 2016-05-18 | 2021-02-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui |
BR112018072034A2 (pt) | 2016-05-24 | 2019-02-12 | Novo Nordisk A/S | compostos mic-1 e usos dos mesmos |
KR102492057B1 (ko) | 2016-06-15 | 2023-01-26 | 노파르티스 아게 | 골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법 |
EP3481416B1 (en) * | 2016-07-08 | 2020-09-09 | CSL Behring Lengnau AG | Subcutaneous administration of long-acting factor ix in humans |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
EP3493832A1 (en) | 2016-08-05 | 2019-06-12 | CSL Behring GmbH | Pharmaceutical formulations of c1 esterase inhibitor |
WO2018037046A1 (en) | 2016-08-23 | 2018-03-01 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
CA3044334A1 (en) * | 2016-11-18 | 2018-05-24 | Institut D'investigacions Biomediques August Pi I Sunyer- Idibaps | Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
MA46968A (fr) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc | Procédés d'induction de tolérance immunitaire à des facteurs de coagulation |
KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
GB2605925B (en) | 2016-12-23 | 2023-02-22 | Harvard College | Gene editing of PCSK9 |
WO2018116267A2 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | Methods of treatment with anti-factor xi/xia antibodies |
US11168147B2 (en) | 2016-12-23 | 2021-11-09 | Novartis Ag | Factor XI antibodies and methods of use |
US20190382462A1 (en) | 2017-01-13 | 2019-12-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
MX2019009063A (es) | 2017-01-31 | 2019-10-21 | Bioverativ Therapeutics Inc | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. |
AU2018218557B9 (en) | 2017-02-08 | 2021-06-24 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
JP2020517657A (ja) | 2017-04-20 | 2020-06-18 | ノヴォ ノルディスク アー/エス | アルブミン融合タンパク質の精製方法 |
TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
CA3063983A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
MX2019014331A (es) | 2017-05-31 | 2020-01-27 | Boehringer Ingelheim Int | Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales. |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
RU2020103424A (ru) | 2017-06-29 | 2021-07-29 | Цсл Беринг Ленгнау Аг | Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения |
US20210346513A1 (en) | 2017-08-04 | 2021-11-11 | Amgen Inc. | Method of conjugation of cys-mabs |
EP3665289A1 (en) | 2017-08-09 | 2020-06-17 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
US20200276283A1 (en) | 2017-09-15 | 2020-09-03 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
JP2020537668A (ja) | 2017-10-18 | 2020-12-24 | シーエスエル リミティド | ヒト血清アルブミン変異体およびその使用 |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
KR20200100116A (ko) | 2017-12-15 | 2020-08-25 | 시에스엘 리미티드 | 신장 섬유증 및/또는 만성 콩팥 질환의 치료에서 FXIIa-억제제의 용도 |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CA3082280A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
US11246908B2 (en) * | 2018-01-10 | 2022-02-15 | The Johns Hopkins University | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof |
TWI802633B (zh) | 2018-01-15 | 2023-05-21 | 大陸商南京傳奇生物科技有限公司 | 針對pd-1之單域抗體及其變異體 |
WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
FI3765525T3 (fi) | 2018-03-13 | 2023-10-16 | Zymeworks Bc Inc | Biparatooppisen her2-vasta-aineen ja lääkkeen konjugaatteja ja käyttömenetelmiä |
RS64455B1 (sr) * | 2018-03-13 | 2023-09-29 | Sepsia Therapeutics S L | Peptidi koji vezuju bakterije, za lečenje infektivnih bolesti i povezanih inflamatornih procesa |
AR115024A1 (es) | 2018-03-28 | 2020-11-18 | Bristol Myers Squibb Co | PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO |
EP3774917A4 (en) | 2018-03-30 | 2022-01-19 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF |
KR102119197B1 (ko) * | 2018-04-23 | 2020-06-05 | 주식회사 엘베이스 | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 |
FI3794024T3 (fi) | 2018-05-14 | 2023-08-10 | Werewolf Therapeutics Inc | Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä |
MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
WO2019222682A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
CN114903978A (zh) | 2018-07-03 | 2022-08-16 | 百时美施贵宝公司 | Fgf-21配制品 |
US20200069817A1 (en) | 2018-08-09 | 2020-03-05 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
US20220056115A1 (en) * | 2018-09-17 | 2022-02-24 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
WO2020069398A1 (en) | 2018-09-27 | 2020-04-02 | Akrevia Therapeutics Inc. | Masked cytokine polypeptides |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
BR112021008200A2 (pt) * | 2018-10-29 | 2021-12-14 | Spin Therapeutics Llc | Composições e métodos para distúrbios de alfa-1-antitripsina |
GB201818477D0 (en) | 2018-11-13 | 2018-12-26 | Emstopa Ltd | Tissue plasminogen activator antibodies and method of use thereof |
CN113396158A (zh) | 2018-11-26 | 2021-09-14 | 诺华股份有限公司 | Lpl-gpihbp1融合多肽 |
JP2022514465A (ja) | 2018-12-06 | 2022-02-14 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ix因子を発現するレンチウイルスベクターの使用 |
CN114174334A (zh) | 2019-03-22 | 2022-03-11 | 反射制药有限公司 | 针对vegf的d-肽化合物 |
CN114144433A (zh) | 2019-03-22 | 2022-03-04 | 反射制药有限公司 | 用于目标蛋白的多价d-肽化合物 |
WO2020198731A2 (en) | 2019-03-28 | 2020-10-01 | Danisco Us Inc | Engineered antibodies |
MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
CU20210096A7 (es) | 2019-05-21 | 2022-06-06 | Novartis Ag | Moléculas de unión a cd19 |
CN113891729A (zh) | 2019-05-24 | 2022-01-04 | 赛诺菲 | 治疗系统性硬化症的方法 |
JP2022537369A (ja) | 2019-06-18 | 2022-08-25 | バイエル アクチェンゲゼルシャフト | 長期安定化のためのアドレノメデュリン-類似体およびその使用 |
EP4025237A1 (en) | 2019-09-06 | 2022-07-13 | Novartis AG | Therapeutic fusion proteins |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
JP2021066730A (ja) | 2019-10-17 | 2021-04-30 | Jcrファーマ株式会社 | 血清アルブミンと成長ホルモンの融合蛋白質の製造方法 |
US20220378882A1 (en) | 2019-10-30 | 2022-12-01 | Jcr Pharmaceuticals Co., Ltd. | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone |
EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
BR112022011513A2 (pt) | 2019-12-13 | 2022-08-23 | Synthekine Inc | Ortólogos de il-2 e métodos de uso |
US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
CR20220586A (es) | 2020-05-19 | 2023-01-09 | Boehringer Ingelheim Int | Moléculas de fijación para el tratamiento de cáncer |
EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
KR20230104651A (ko) | 2020-11-06 | 2023-07-10 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
WO2022166720A1 (zh) * | 2021-02-05 | 2022-08-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
AU2022224636A1 (en) | 2021-02-19 | 2023-09-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
CN114133458B (zh) * | 2021-12-08 | 2023-11-14 | 福州大学 | 一种在人血清白蛋白内部融合多肽的方法 |
TW202400658A (zh) | 2022-04-26 | 2024-01-01 | 瑞士商諾華公司 | 靶向il—13和il—18的多特異性抗體 |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Family Cites Families (517)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625041A (en) * | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4363877B1 (en) | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
US4440859A (en) * | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4264731A (en) * | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
US4283489A (en) | 1977-09-23 | 1981-08-11 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
US4407948A (en) | 1977-09-23 | 1983-10-04 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4652525A (en) * | 1978-04-19 | 1987-03-24 | The Regents Of The University Of California | Recombinant bacterial plasmids containing the coding sequences of insulin genes |
US4447538A (en) * | 1978-04-19 | 1984-05-08 | Regents Of The University Of California | Microorganism containing gene for human chorionic somatomammotropin |
US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
NZ195980A (en) | 1980-01-08 | 1984-10-19 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing leukocyte interferon-like polypeptides;pharmaceutical and veterinary compositions |
JP2687995B2 (ja) | 1980-04-03 | 1997-12-08 | バイオゲン インコーポレイテッド | Dna配列、組替えdna分子およびヒト繊維芽細胞インターフェロン様ポリペプチドの製造方法 |
DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
FR2490675B1 (fr) | 1980-09-25 | 1985-11-15 | Genentech Inc | Production microbienne d'interferon de fibroplaste humain |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
WO1982002715A1 (fr) | 1981-02-04 | 1982-08-19 | Sugano Haruo | Gene d'interferon (beta)humain |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
JPS57149228A (en) | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4792602A (en) | 1981-06-19 | 1988-12-20 | Cornell Research Foundation, Inc. | Adaptors, and synthesis and cloning of proinsulin genes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0079739A3 (en) | 1981-11-12 | 1984-08-08 | The Upjohn Company | Albumin-based nucleotides, their replication and use, and plasmids for use therein |
EP0091527A3 (en) | 1981-12-14 | 1984-07-25 | The President And Fellows Of Harvard College | Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4778879A (en) | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
US4499188A (en) * | 1982-05-05 | 1985-02-12 | Cetus Corporation | Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
FI82266C (fi) | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
EP0116201B1 (en) | 1983-01-12 | 1992-04-22 | Chiron Corporation | Secretory expression in eukaryotes |
US4840934A (en) * | 1983-01-25 | 1989-06-20 | Eleanor Roosevelt Institute For Cancer Research, Inc. | Therapeutic method using T cell growth factor |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5015575A (en) * | 1983-04-07 | 1991-05-14 | Chiron Corporation | Hybrid DNA synthesis of insulin |
US4914026A (en) * | 1983-04-07 | 1990-04-03 | Chiron Corporation | Alpha factor leader sequence directed secretion of insulin |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
WO1984004330A1 (en) | 1983-04-22 | 1984-11-08 | Amgen | Secretion of exogenous polypeptides from yeast |
NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
US5010003A (en) * | 1983-04-25 | 1991-04-23 | Genentech, Inc. | Use of yeast homologous signals to secrete heterologous proteins |
CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4576813A (en) | 1983-07-05 | 1986-03-18 | Monsanto Company | Heat recovery from concentrated sulfuric acid |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
JPS6087792A (ja) | 1983-09-23 | 1985-05-17 | ジェネックス・コーポレイション | 雑種制御領域 |
EP0142641B1 (de) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
US4518564A (en) * | 1983-10-03 | 1985-05-21 | Jeneric Industries, Inc. | Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
GB8334261D0 (en) | 1983-12-22 | 1984-02-01 | Bass Plc | Fermentation processes |
JPS60136596A (ja) | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
FR2564106B1 (fr) * | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
EP0172619A1 (en) | 1984-06-20 | 1986-02-26 | Takeda Chemical Industries, Ltd. | Novel transformant and use thereof |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5908763A (en) | 1984-07-06 | 1999-06-01 | Novartis Corporation | DNA encoding GM-CSF and a method of producing GM-CSF protein |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US4716217A (en) | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
US4734491A (en) | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
FR2579224B1 (fr) * | 1985-03-25 | 1987-05-22 | Genetica | Procede de preparation microbiologique de la serum-albumine humaine |
US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
ATE63757T1 (de) | 1985-03-28 | 1991-06-15 | Chiron Corp | Expression durch verwendung von fusionsgenen fuer proteinproduktion. |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
AU5890286A (en) | 1985-06-17 | 1986-12-24 | Genex Corp. | Cloned human serum albumin gene |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
US5641663A (en) * | 1985-11-06 | 1997-06-24 | Cangene Corporation | Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces |
CA1295566C (en) | 1987-07-21 | 1992-02-11 | Robert T. Garvin | Characterization and structure of genes for protease a and protease b from streptomyces griseus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
FR2594846B1 (fr) * | 1986-02-21 | 1989-10-20 | Genetica | Procede de preparation de la serum albumine humaine mature |
EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IT1203758B (it) | 1986-03-27 | 1989-02-23 | Univ Roma | Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DK179286D0 (da) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
US4765980A (en) * | 1986-04-28 | 1988-08-23 | International Minerals & Chemical Corp. | Stabilized porcine growth hormone |
US4859609A (en) | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
IT1204400B (it) * | 1986-06-20 | 1989-03-01 | Sclavo Spa | Composizioni farmaceutiche contenente una calcitonina |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
IT1196484B (it) | 1986-07-11 | 1988-11-16 | Sclavo Spa | Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
GB8620926D0 (en) * | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
AU624789B2 (en) | 1987-02-19 | 1992-06-25 | Amgen, Inc. | Purified platelet-derived growth factor and methods for purification thereof |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
JP2873012B2 (ja) * | 1987-04-09 | 1999-03-24 | デルタ バイオテクノロジー リミテッド | 酵母ベクター |
EP0288307B1 (en) | 1987-04-22 | 1996-09-04 | Chiron Corporation | Recombinant production of PDGF A-chain polypeptides |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
NZ225597A (en) | 1987-07-28 | 1991-08-27 | Gist Brocades Nv | Use of kluyveromyces in the production of chymosin, tpa, hsa and other proteins |
JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
SE459586B (sv) | 1987-09-14 | 1989-07-17 | Mta Szegedi Biolog Koezponti | Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JPH0811074B2 (ja) | 1987-10-30 | 1996-02-07 | 財団法人化学及血清療法研究所 | プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法 |
JP2791418B2 (ja) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えdna、形質転換体 |
ZA89430B (en) | 1988-01-22 | 1989-10-25 | Gen Hospital Corp | Cloned genes encoding ig-cd4 fusion proteins and the use thereof |
JPH01240191A (ja) * | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現 |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
US5066489A (en) | 1988-03-28 | 1991-11-19 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US4999339A (en) * | 1988-03-28 | 1991-03-12 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5061488A (en) | 1988-04-15 | 1991-10-29 | The United States Of America As Represented Department Of Health & Human Services | Flavone-8-acetic acid and interleukin-2 for cancer therapy |
US5096707A (en) * | 1988-04-15 | 1992-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
IL89992A0 (en) | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of human serum albumin in methylotrophic yeasts |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
DE353450T1 (de) | 1988-06-24 | 1990-09-06 | The Dow Chemical Co., Midland, Mich. | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikoerper. |
US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
JP3092811B2 (ja) | 1988-07-23 | 2000-09-25 | デルタ バイオテクノロジー リミテッド | ペプチドおよびdna配列 |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
FR2635115B1 (fr) | 1988-08-05 | 1992-04-03 | Rhone Poulenc Sante | Procede de preparation de la serum albumine humaine a partir d'une levure |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5260202A (en) | 1988-09-07 | 1993-11-09 | Delta Biotechnology Limited | Fermentation method |
JPH02227079A (ja) | 1988-10-06 | 1990-09-10 | Tonen Corp | ヒト血清アルブミン断片 |
US5298243A (en) | 1988-10-20 | 1994-03-29 | Denki Kagaku Kogyo Kabushiki Kaisha | Colony stimulating factor-gelatin conjugate |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
JPH02117384A (ja) | 1988-10-26 | 1990-05-01 | Tonen Corp | 酵母宿主によるヒト血清アルブミンaの製造 |
US5759802A (en) | 1988-10-26 | 1998-06-02 | Tonen Corporation | Production of human serum alubumin A |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5256410A (en) | 1988-12-01 | 1993-10-26 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK105489D0 (da) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
EP1026253B2 (en) | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
EP0392300B1 (de) * | 1989-04-11 | 1992-08-26 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen |
EP0395918A3 (en) | 1989-04-13 | 1991-10-23 | Vascular Laboratory, Inc. | Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
DE69024261T2 (de) | 1989-05-24 | 1996-07-18 | Merck & Co Inc | Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors |
US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
DE69021335T2 (de) * | 1989-06-09 | 1996-04-11 | Gropep Pty. Ltd., Adelaide | Wachstumshormonfusionsproteine. |
JPH0327320A (ja) | 1989-06-26 | 1991-02-05 | Ajinomoto Co Inc | ヒトb細胞分化因子医薬組成物 |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
CU22222A1 (es) | 1989-08-03 | 1995-01-31 | Cigb | Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6063373A (en) * | 1989-09-19 | 2000-05-16 | Maxim Pharmaceuticals, Inc. | Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン,インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
FR2653020B1 (fr) | 1989-10-17 | 1993-03-26 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies. |
GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
JPH03201987A (ja) | 1989-12-29 | 1991-09-03 | Tonen Corp | ヒト血清アルブミン断片 |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
EP0439442B1 (en) * | 1990-01-25 | 1996-03-06 | Washington University | Factor x-laci hybrid protein |
JPH04211375A (ja) | 1990-02-05 | 1992-08-03 | Ajinomoto Co Inc | 合成遺伝子及びそれを用いたヒト血清アルブミンの製造法 |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5208018A (en) * | 1990-03-19 | 1993-05-04 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
DE59101397D1 (de) | 1990-07-10 | 1994-05-19 | Boehringer Ingelheim Int | O-glycosyliertes ifn-alpha. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5225341A (en) | 1990-07-19 | 1993-07-06 | The Regents Of The University Of California | Biologically safe plant transformation system using a ds transposon |
US5202239A (en) * | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
US5071872A (en) | 1990-08-14 | 1991-12-10 | The Ohio State University Research Foundation | Method for improving interleukin-2 activity using aci-reductone compounds |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5391183A (en) * | 1990-09-21 | 1995-02-21 | Datascope Investment Corp | Device and method sealing puncture wounds |
IT1242149B (it) | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
FR2668368B1 (fr) | 1990-10-30 | 1995-03-10 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales. |
JPH0638771A (ja) | 1990-10-31 | 1994-02-15 | Tonen Corp | ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法 |
US5353535A (en) | 1990-11-05 | 1994-10-11 | Plumly George W | Floor type advertising apparatus |
WO1992009691A1 (fr) | 1990-11-29 | 1992-06-11 | Institut National De La Recherche Agronomique - I.N.R.A. | Nouveaux variants derives des interferons de type i, leur procede de production, et leurs applications |
US5272080A (en) * | 1991-02-19 | 1993-12-21 | Pharmavene, Inc. | Production of butyrylcholinesterase |
US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5272070A (en) * | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
CA2062659A1 (en) | 1991-03-12 | 1992-09-13 | Yasutaka Igari | Composition for sustained-release of erythropoietin |
US5817471A (en) | 1991-03-14 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
CA2064331C (en) | 1991-03-28 | 2003-02-18 | Marvin L. Bayne | Vascular endothelial cell growth factor c subunit |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
EP0509841A3 (en) | 1991-04-18 | 1993-08-18 | Tonen Corporation | Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
US5330901A (en) | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
FR2676070B1 (fr) | 1991-04-30 | 1994-09-30 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisation. |
US5646012A (en) * | 1991-04-30 | 1997-07-08 | Rhone-Poulenc Rorer S.A. | Yeast promoter and use thereof |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5304473A (en) * | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
FR2677996B1 (fr) | 1991-06-21 | 1993-08-27 | Rhone Poulenc Rorer Sa | Vecteurs de clonage et/ou d'expression preparation et utilisation. |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
JPH05292972A (ja) | 1991-07-29 | 1993-11-09 | Tonen Corp | 改良された酵母発現系 |
US5723719A (en) | 1991-08-08 | 1998-03-03 | Health Research Inc. | Transgenic mouse as model for diseases involving dopaminergic dysfunction |
DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
EP0611306B1 (en) * | 1991-11-08 | 1998-07-08 | Somatogen, Inc. | Hemoglobins as drug delivery agents |
US5786883A (en) * | 1991-11-12 | 1998-07-28 | Pilkington Barnes Hind, Inc. | Annular mask contact lenses |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US6348327B1 (en) * | 1991-12-06 | 2002-02-19 | Genentech, Inc. | Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells |
US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
ATE243746T1 (de) | 1992-01-07 | 2003-07-15 | Elan Pharm Inc | Transgene tiermodelle fur alzheimer-krankheit |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
US5230886A (en) | 1992-03-18 | 1993-07-27 | Trustees Of Boston University | Tumor cell suppression |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5460954A (en) | 1992-04-01 | 1995-10-24 | Cheil Foods & Chemicals, Inc. | Production of human proinsulin using a novel vector system |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
RU2135720C1 (ru) | 1992-06-09 | 1999-08-27 | Хоппе Аг | Запирающее устройство |
US5686268A (en) * | 1992-06-19 | 1997-11-11 | Pfizer Inc. | Fused proteins |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
JP3269504B2 (ja) | 1992-07-08 | 2002-03-25 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの製造方法 |
FR2694294B1 (fr) | 1992-07-30 | 1994-09-09 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisateur. |
AU686567C (en) | 1992-07-31 | 2002-08-08 | Genentech Inc. | Human growth hormone aqueous formulation |
US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
DE4226971C2 (de) * | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
US5731490A (en) | 1992-09-29 | 1998-03-24 | The Ontario Cancer Institute | Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1) |
WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
FR2701953B1 (fr) | 1993-02-22 | 1995-05-24 | Centre Nat Rech Scient | Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant. |
US5441734A (en) * | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
US5780021A (en) | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
JPH08510746A (ja) * | 1993-05-21 | 1996-11-12 | ザイモジェネティクス,インコーポレイティド | 改良型▲vii▼因子 |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
DK82893D0 (da) * | 1993-07-08 | 1993-07-08 | Novo Nordisk As | Peptid |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5459031A (en) | 1993-11-05 | 1995-10-17 | Amgen Inc. | Methods for controlling sialic acid derivatives in recombinant glycoproteins |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
WO1995020401A1 (en) | 1994-01-31 | 1995-08-03 | Trustees Of Boston University | Polyclonal antibody libraries |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
US5646113A (en) | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
FR2719593B1 (fr) | 1994-05-06 | 1996-05-31 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant. |
GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
US5639642A (en) * | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
JPH0851982A (ja) | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | ヒト血清アルブミンをコードする改変された遺伝子 |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US6071923A (en) * | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
WO1996014328A1 (en) | 1994-11-07 | 1996-05-17 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
FR2726576B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante |
FR2726471B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
AT403167B (de) * | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
US5695750A (en) | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
EP1621206A1 (en) * | 1994-12-12 | 2006-02-01 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US5837281A (en) * | 1995-03-17 | 1998-11-17 | Takeda Chemical Industries, Ltd. | Stabilized interface for iontophoresis |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2363695A (en) | 1995-04-27 | 1996-11-18 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
KR19990008335A (ko) | 1995-05-05 | 1999-01-25 | 로버트 에리치. 벤슨 | 인체 케모킨 베타-8, 케모킨 베타-1 및 대식세포 염증 단백질-4 |
US5728915A (en) | 1995-05-08 | 1998-03-17 | Children's Hospital, Inc. | Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter |
US5705151A (en) | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US6001625A (en) | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
US5741815A (en) * | 1995-06-02 | 1998-04-21 | Lai; Ching-San | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
CA2236591C (en) | 1995-11-02 | 2012-01-03 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6110707A (en) | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
US6150337A (en) | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6045788A (en) * | 1996-02-28 | 2000-04-04 | Cornell Research Foundation, Inc. | Method of stimulation of immune response with low doses of IL-2 |
DE19639601A1 (de) | 1996-02-28 | 1997-09-04 | Bayer Ag | Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen |
US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
JP3794748B2 (ja) * | 1996-03-04 | 2006-07-12 | 第一アスビオファーマ株式会社 | メタノール代謝系を有する微生物の培養法 |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
AU5711196A (en) | 1996-03-14 | 1997-10-01 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
AU728146B2 (en) | 1996-03-14 | 2001-01-04 | Immune Response Corporation, The | Targeted delivery of genes encoding interferon |
CA2248136A1 (en) * | 1996-03-21 | 1997-09-25 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor i, ii and iii |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
US6204022B1 (en) * | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
EP0966971A1 (en) * | 1996-04-23 | 1999-12-29 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient |
DE69703294T2 (de) * | 1996-05-22 | 2001-05-17 | Protarga Inc | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten |
US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
EP0917566B1 (de) * | 1996-06-11 | 2004-09-22 | Roche Diagnostics GmbH | Rekombinante blutgerinnungsproteasen |
WO1998002543A1 (fr) | 1996-07-15 | 1998-01-22 | Chugai Research Institute For Molecular Medicine, Inc. | Nouveaux facteurs analogues au vegf |
DK0961831T3 (da) | 1996-08-16 | 2009-01-12 | Human Genome Sciences Inc | Humant alfa-endokin |
DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
EP0961832A4 (en) * | 1996-09-18 | 2003-02-26 | Human Genome Sciences Inc | HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES |
US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US5994112A (en) | 1996-10-09 | 1999-11-30 | Incyte Pharmaceuticals, Inc. | Human protein tyrosine kinase |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US5955508A (en) * | 1996-10-15 | 1999-09-21 | Loyola University Of Chicago | Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens |
AU4988697A (en) | 1996-10-24 | 1998-05-15 | Vion Pharmaceuticals, Inc. | Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents |
PT939804E (pt) | 1996-10-25 | 2005-11-30 | Human Genome Sciences Inc | Neutroquina alfa |
JPH10134761A (ja) | 1996-10-30 | 1998-05-22 | Ebara Corp | イオン注入装置及びイオン注入方法 |
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
GB9623205D0 (en) * | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US5833994A (en) | 1997-01-08 | 1998-11-10 | Paracelsian, Inc. | Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection |
ATE321855T1 (de) | 1997-01-14 | 2006-04-15 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
EP0954589A1 (en) * | 1997-01-24 | 1999-11-10 | Novo Nordisk A/S | Synthetic leader peptide sequences |
ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
GB2324529A (en) | 1997-02-21 | 1998-10-28 | Merck & Co Inc | A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases |
US7026447B2 (en) | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
CZ294425B6 (cs) | 1997-04-14 | 2005-01-12 | Micromet Ag | Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor |
TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050347A1 (en) | 1997-05-05 | 1998-11-12 | The Regents Of The University Of California | Naphthols useful in antiviral methods |
EP1003767A4 (en) | 1997-05-30 | 2003-01-02 | Human Genome Sciences Inc | TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR |
US6071743A (en) | 1997-06-02 | 2000-06-06 | Subsidiary No. 3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
AU7830398A (en) | 1997-06-11 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr9 |
GB9713412D0 (en) | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
US5858719A (en) | 1997-07-17 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding human ATP binding-cassette transport protein and methods of use |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
DE69801970T2 (de) | 1997-09-21 | 2002-06-13 | Schering Corp | Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6201072B1 (en) * | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
CA2305690A1 (en) * | 1997-10-09 | 1999-04-22 | Human Genome Sciences, Inc. | 53 human secreted proteins |
EP1042343B1 (en) | 1997-11-03 | 2008-01-23 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
EP1037927B1 (en) * | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
WO1999029314A1 (en) * | 1997-12-08 | 1999-06-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
DE19813802A1 (de) | 1998-03-27 | 1999-11-11 | Retro Tech Gmbh | Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen |
GB9806631D0 (en) | 1998-03-28 | 1998-05-27 | Safeglass Europ Limited | Safetyglass |
US6251868B1 (en) | 1998-04-30 | 2001-06-26 | Teijin Limited | Method for treating a human immunodeficiency virus infection |
CZ300540B6 (cs) | 1998-05-15 | 2009-06-10 | Schering Corporation | Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1 |
CN1119352C (zh) | 1998-05-15 | 2003-08-27 | 中国科学院上海生物化学研究所 | 人血清白蛋白在毕赤酵母中的表达与纯化 |
US5970300A (en) * | 1998-06-01 | 1999-10-19 | Xerox Corporation | Apparatus for applying scents to paper in a printer/copier |
EP1088084B1 (en) * | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
CN1105727C (zh) | 1998-06-17 | 2003-04-16 | 上海海济医药生物工程有限公司 | 重组人血清白蛋白的生产方法 |
WO1999066936A1 (en) | 1998-06-24 | 1999-12-29 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
GB9817084D0 (en) | 1998-08-06 | 1998-10-07 | Wood Christopher B | A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders |
US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
US6193997B1 (en) * | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
US7465785B2 (en) * | 1999-03-08 | 2008-12-16 | Genentech, Inc. | Polypeptide encoded by a nucleic acid over-expressed in melanoma |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
BR0010725A (pt) | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
US20020048571A1 (en) * | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
WO2001029242A2 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
EP2267026A1 (en) * | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
US7070973B2 (en) | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050244931A1 (en) | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2446739A1 (en) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
US7186797B2 (en) | 2001-08-10 | 2007-03-06 | Epix Pharmaceuticals, Inc. | Polypeptide conjugates with extended circulating half-lives |
WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2279755B1 (en) * | 2001-10-10 | 2014-02-26 | ratiopharm GmbH | Remodelling and glycoconjugation of Fibroblast Growth Factor (FGF) |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003054182A2 (en) | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20080167238A1 (en) | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
WO2004075931A2 (en) * | 2003-02-27 | 2004-09-10 | Baxter International Inc. | Method for the validatable inactivation of pathogens in a biological fluid by irradiation |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
US7436410B2 (en) * | 2005-04-01 | 2008-10-14 | Seiko Epson Corporation | System and method for programming a controller |
MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
US7438904B1 (en) | 2005-10-04 | 2008-10-21 | University Of Kentucky Research Foundation | High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same |
US8008257B2 (en) | 2005-10-20 | 2011-08-30 | University Of Ottawa Heart Institute | ANF fusion proteins |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
BRPI0712383A2 (pt) | 2006-06-07 | 2012-07-10 | Human Genome Sciences Inc | proteìnas de fusão da albumina |
AU2012267484B2 (en) * | 2011-06-10 | 2017-03-23 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
-
2001
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Application Discontinuation
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Application Discontinuation
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en active Application Filing
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en active Application Filing
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en active Application Filing
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Application Discontinuation
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Application Discontinuation
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
-
2007
- 2007-10-29 US US11/927,602 patent/US10080785B2/en active Active
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
-
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
-
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
-
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
-
2013
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Lifetime
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
-
2016
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
-
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned